BioSpace News Archive

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”), a biotechnology company pioneering its patented Botanical Synthesis technology platform

Gilgamesh Pharmaceuticals today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders.

Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported new data highlighting the potential of the CAN10 antibody, currently in phase I clinical development, as therapy in systemic sclerosis.

The Glioblastoma Foundation is proud to be a charity partner for the 2024 Los Angeles Marathon for the 5th year.

Pharming Group N.V. presents its preliminary financial report for the three months and full year ended December 31, 2023.

Relation Therapeutics, a biotechnology company at the forefront of leveraging computational and experimental approaches to drug discovery, announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.

Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence -powered approaches with applications in precision oncology drug research and development.

Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, announced new data at EUROGIN International Multidisciplinary HPV Congress 2024, taking place in Stockholm on March 13-16.

First Wave BioPharma, Inc. announced it has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that the Axonics R20™ rechargeable sacral neuromodulation system has received CE Mark approval.